How Methotrexate Affects the Body and Risk Factors for Toxicity
At a Glance
Methotrexate toxicity often occurs when the drug builds up in the body due to incorrect daily dosing, poor kidney function, or interactions with common drugs like NSAIDs and PPIs. Taking methotrexate on a strict weekly schedule is essential to allow healthy cells to recover.
Understanding how methotrexate (MTX) interacts with your body is key to using it safely. Unlike many medications that work on a simple “on/off” switch, methotrexate targets the very machinery your cells use to build DNA.
How Methotrexate Works: The “Folate Trap”
Methotrexate works by “starving” cells of the building blocks they need to grow. It does this by blocking an enzyme called dihydrofolate reductase (DHFR) [1].
- DHFR Inhibition: This enzyme’s job is to create active folates, which are essential for making nucleotides (the building blocks of DNA) [2].
- Cellular Arrest: When MTX blocks this enzyme, it creates a “folate trap.” Without active folates, cells cannot repair or replicate their DNA, leading to a shortage of nucleotides and eventual cell death [2][3].
- The Recovery Window: This is why weekly dosing is critical for rheumatology patients. A once-a-week dose provides a “recovery window,” allowing healthy cells (like those in your mouth and bone marrow) to regenerate. Taking the medication daily by mistake prevents this recovery, leading to life-threatening toxicity [4][5].
The Kidney’s “Pumps” and Drug Interactions
Your kidneys are responsible for clearing MTX from your body. They use specialized proteins called Organic Anion Transporters (OAT1 and OAT3) to “pump” the drug from your blood into your urine [6].
The Danger of “Clogging” the Pumps
If these pumps are blocked, MTX stays in your blood for much longer, which can damage the kidneys and other organs. Certain common drugs can “compete” for these pumps:
- NSAIDs (Ibuprofen, Naproxen): These common pain relievers can “clog” the OAT1 and OAT3 pumps, significantly slowing down how fast your body clears MTX [6]. Important Context: In high-dose oncology treatments, NSAIDs are strictly prohibited. In low-dose rheumatology treatments, patients often use NSAIDs concurrently, but this must be closely monitored by a doctor. If you are concerned, ask your doctor if alternatives like acetaminophen (Tylenol) are safer for you.
- PPIs (Omeprazole, Pantoprazole): Some evidence suggests that Proton Pump Inhibitors (stomach acid drugs) may also delay MTX clearance by interfering with these renal pumps [7].
- Penicillins: Certain antibiotics (like penicillin and piperacillin-tazobactam) can also interfere with renal clearance, keeping MTX levels dangerously high [8].
Patient-Specific Risk Factors
Beyond the dose you take, your body’s unique biology affects your risk.
“Third-Spacing”: The Hidden Reservoir
If you have fluid collections in your body—such as pleural effusions (fluid around the lungs) or ascites (fluid in the abdomen)—MTX can get trapped in these fluids [9].
- This is known as third-spacing. The fluid acts like a “hidden reservoir,” slowly leaking MTX back into your bloodstream over several days [9].
- This leads to prolonged exposure that can cause severe toxicity even if your initial dose was correct.
Genetics and MTHFR
Your genes play a role in how well your body processes folate.
- Variants in the MTHFR gene (specifically the C677T variant) have been linked to an increased risk of side effects in some patients [10][11].
- These genetic changes can make you more sensitive to the “folate trap” caused by MTX [12].
Renal Function and Age
As you age, your kidney’s ability to pump out waste naturally decreases. Patients over age 55 or those with pre-existing kidney disease must be monitored much more closely because their OAT pumps may not work at full capacity [4][13].
Common questions in this guide
Why must methotrexate be taken weekly instead of daily?
Can I take ibuprofen or other NSAIDs with methotrexate?
How does fluid retention or swelling affect methotrexate levels?
Do stomach acid medications or PPIs interact with methotrexate?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given that I have swelling or fluid retention, how will you adjust my methotrexate monitoring to account for 'third-spacing'?
- 2.Are there specific stomach acid medications (like H2 blockers) I can take that won't interfere with my kidney's ability to clear methotrexate?
- 3.Can you review all my current supplements to ensure I'm not taking anything that competes with the OAT1 or OAT3 transporters in my kidneys?
- 4.If I need to avoid NSAIDs for pain, is acetaminophen (Tylenol) a safe alternative for me?
- 5.Do you recommend genetic testing for MTHFR variants before I continue or increase my dose?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Investigation on inhibitory effect of folic acid on methotrexate-induced epithelial-mesenchymal transition focusing on dihydrofolate reductase.
Kawami M, Honda N, Hara T, et al.
Drug metabolism and pharmacokinetics 2019; (34(6)):396-399 doi:10.1016/j.dmpk.2019.08.003.
PMID: 31601464 - 2
DNA Double-Strand Breaks Affect Chromosomal Rearrangements during Methotrexate-Mediated Gene Amplification in Chinese Hamster Ovary Cells.
Baik JY, Han HJ, Lee KH
Pharmaceutics 2021; (13(3)) doi:10.3390/pharmaceutics13030376.
PMID: 33809068 - 3
Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation.
Aoki Y, Tome Y, Han Q, et al.
Biochemistry and biophysics reports 2021; (28()):101177 doi:10.1016/j.bbrep.2021.101177.
PMID: 34877414 - 4
Mucocutaneous Adverse Effects of Methotrexate Toxicity: A Case Series.
Subedi B, Bhandari S, Timilsina S, et al.
JNMA; journal of the Nepal Medical Association 2025; (63(283)):189-194 doi:10.31729/jnma.8905.
PMID: 40656915 - 5
A Clinical Case of Methotrexate Toxicity.
Peixoto AC, de Almeida Mota R, Rodrigues ALM, et al.
Journal of medical cases 2025; (16(8)):314-317 doi:10.14740/jmc5159.
PMID: 40904756 - 6
Inhibition of Methotrexate Uptake via Organic Anion Transporters OAT1 and OAT3 by Glucuronides of Nonsteroidal Anti-inflammatory Drugs.
Iwaki M, Shimada H, Irino Y, et al.
Biological & pharmaceutical bulletin 2017; (40(6)):926-931 doi:10.1248/bpb.b16-00970.
PMID: 28566636 - 7
Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis.
Wang X, Song Y, Wang J, et al.
International journal of clinical pharmacy 2020; (42(1)):23-30 doi:10.1007/s11096-019-00958-5.
PMID: 31916121 - 8
Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient.
Krämer I, Rosentreter J, Fried M, Kühn M
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021; (27(4)):1000-1004 doi:10.1177/1078155220953878.
PMID: 32878553 - 9
Identifying risk factors for methotrexate-induced acute kidney injury despite full prevention in patients with primary central nervous system lymphoma.
Lin WY, Tsai CK, Yeh CM, Liu CJ
Toxicology and applied pharmacology 2025; (502()):117436 doi:10.1016/j.taap.2025.117436.
PMID: 40482892 - 10
Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.
Chaabane S, Marzouk S, Akrout R, et al.
European journal of drug metabolism and pharmacokinetics 2016; (41(4)):385-93 doi:10.1007/s13318-015-0288-z.
PMID: 26077125 - 11
Association Between MTHFR C677T Polymorphism and Methotrexate Treatment Outcome in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.
Shao W, Yuan Y, Li Y
Genetic testing and molecular biomarkers 2017; (21(5)):275-285 doi:10.1089/gtmb.2016.0326.
PMID: 28277784 - 12
Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
Kałużna E, Strauss E, Zając-Spychała O, et al.
European journal of pharmacology 2015; (769()):93-9.
PMID: 26528799 - 13
Single Low-Dose Methotrexate and Vitamin B12 Deficiency-Induced Pancytopenia Causing Fatality: A Case Report.
Akhdar G, Akpan I, Myles A, Atencah SE
Cureus 2024; (16(6)):e63528 doi:10.7759/cureus.63528.
PMID: 39081409
This page provides educational information about methotrexate toxicity and risk factors. Always consult your rheumatologist, oncologist, or prescribing doctor before changing your medication schedule, painkillers, or supplements.
Get notified when new evidence is published on Methotrexate toxicity.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.